IPSC vs. OPT, BCAB, JSPR, PSTX, GRPH, CCCC, GMDA, GRTS, VXRT, and ABOS
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Opthea (OPT), BioAtla (BCAB), Jasper Therapeutics (JSPR), Poseida Therapeutics (PSTX), Graphite Bio (GRPH), C4 Therapeutics (CCCC), Gamida Cell (GMDA), Gritstone bio (GRTS), Vaxart (VXRT), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "biological products, except diagnostic" industry.
Century Therapeutics vs.
Opthea (NASDAQ:OPT) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.
Opthea has a net margin of 0.00% compared to Century Therapeutics' net margin of -2,127.33%. Opthea's return on equity of 0.00% beat Century Therapeutics' return on equity.
Opthea currently has a consensus target price of $22.50, suggesting a potential upside of 614.29%. Century Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 468.86%. Given Opthea's higher possible upside, equities analysts plainly believe Opthea is more favorable than Century Therapeutics.
13.9% of Opthea shares are held by institutional investors. Comparatively, 35.8% of Century Therapeutics shares are held by institutional investors. 3.2% of Opthea shares are held by insiders. Comparatively, 7.6% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Opthea's average media sentiment score of 0.00 equaled Century Therapeutics' average media sentiment score.
Opthea has higher earnings, but lower revenue than Century Therapeutics.
Opthea has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
Century Therapeutics received 8 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 59.46% of users gave Century Therapeutics an outperform vote while only 51.85% of users gave Opthea an outperform vote.
Summary
Century Therapeutics beats Opthea on 7 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Century Therapeutics Competitors List
Related Companies and Tools